Dengue Rapid Test Outlook: Point-of-Care Diagnostics & 6.3% CAGR to 2032
公開 2026/04/08 15:49
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Dengue Rapid Test - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Dengue Rapid Test market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: Dengue fever affects 100–400 million people annually, but traditional lab-based diagnostics (PCR, ELISA) take hours to days and require centralized facilities. Dengue rapid tests solve this with immunochromatography-based POCT devices delivering results in 15–20 minutes at the point of care. Key adoption barriers include variable sensitivity/specificity across serotypes, raw material costs (monoclonal antibodies), and distribution challenges in endemic regions.
The global market for Dengue Rapid Test was estimated to be worth US$ 626 million in 2025 and is projected to reach US$ 952 million, growing at a CAGR of 6.3% from 2026 to 2032.
Dengue Rapid Test is an in vitro diagnostic (IVD) product based on immunochromatography or other rapid immunoassay techniques. It is used to detect dengue virus antigens (NS1) or antibodies (IgM/IgG) in human samples within 15–20 minutes, enabling rapid screening or auxiliary diagnosis of dengue infection.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6450968/dengue-rapid-test
Market Segmentation & Key Players
The Dengue Rapid Test market is segmented as below:
Leading Suppliers: Abbott, SD Biosensor, bioMérieux, CTK Biotech, Wondfo, Roche Diagnostics, ACON Biotech, InBios International, Bio-Rad Laboratories, DiaSorin Group, Siemens Healthineers, Thermo Fisher Scientific, Reszon Diagnostics International.
Segment by Type: NS1 Antigen Detection | IgM Antibody Detection | IgG Antibody Detection | Others
Segment by Application: Healthcare Industry | Public Health Sector | Others
Exclusive Industry Insights
Gross profit margin stratification: As a typical POCT IVD product, dengue rapid tests exhibit a stratified margin structure:
OEM/white-label supply (35–50% margin): Price-sensitive, large-volume bidding.
Own-brand + registration + distribution (50–65% margin): Brand premium and channel value.
Hospital terminal + government/international procurement (65–80% margin): Highest margins through brand and technical endorsement.
Technical bottleneck – NS1 sensitivity across serotypes: Dengue has four distinct serotypes (DENV-1 to DENV-4). Many rapid tests show 85–90% sensitivity for DENV-2 but only 65–75% for DENV-1 or DENV-3. High-quality NS1 tests (Abbott, SD Biosensor) use multiple monoclonal antibodies targeting conserved epitopes, achieving >92% sensitivity across all serotypes but at 2–3x higher cost.
Recent 6-month data (Oct 2025 – Mar 2026):
NS1 antigen detection fastest-growing (CAGR 8.2%), preferred for early diagnosis (days 1–5 of symptoms).
Combination tests (NS1 + IgM/IgG) now 45% of market, up from 28% in 2023.
Average price declined from US$ 4.50 to US$ 3.80 per test due to Chinese supplier competition.
User case – National dengue control program (Brazil, 5,000 health posts): Deploying NS1 rapid tests for suspected cases reduced average time-to-diagnosis from 3 days (lab confirmation) to 30 minutes. Early case detection improved patient outcomes (reduced progression to severe dengue by 28%). Program cost: US$ 12M annually; estimated hospitalization savings: US$ 28M.
Industry drivers: Climate change expanding mosquito vector range; healthcare systems shifting from confirmatory to screening diagnosis; international organization procurement (PAHO, WHO, UNICEF) for outbreak response; multi-pathogen testing (dengue + Zika + chikungunya) gaining traction.
Regional snapshot: Asia-Pacific leads with 52% revenue share (endemic: India, Thailand, Philippines, Indonesia). Latin America (Brazil, Mexico, Colombia) holds 28%. Africa fastest-growing (CAGR 8.5%) with expanding surveillance programs.
Conclusion
The dengue rapid test market grows steadily, driven by disease expansion, primary healthcare POCT adoption, and public health investment. Success depends on improving NS1 sensitivity across all serotypes, reducing raw material costs, and securing international procurement contracts. The projected US$ 952 million market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
Addressing core industry needs: Dengue fever affects 100–400 million people annually, but traditional lab-based diagnostics (PCR, ELISA) take hours to days and require centralized facilities. Dengue rapid tests solve this with immunochromatography-based POCT devices delivering results in 15–20 minutes at the point of care. Key adoption barriers include variable sensitivity/specificity across serotypes, raw material costs (monoclonal antibodies), and distribution challenges in endemic regions.
The global market for Dengue Rapid Test was estimated to be worth US$ 626 million in 2025 and is projected to reach US$ 952 million, growing at a CAGR of 6.3% from 2026 to 2032.
Dengue Rapid Test is an in vitro diagnostic (IVD) product based on immunochromatography or other rapid immunoassay techniques. It is used to detect dengue virus antigens (NS1) or antibodies (IgM/IgG) in human samples within 15–20 minutes, enabling rapid screening or auxiliary diagnosis of dengue infection.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6450968/dengue-rapid-test
Market Segmentation & Key Players
The Dengue Rapid Test market is segmented as below:
Leading Suppliers: Abbott, SD Biosensor, bioMérieux, CTK Biotech, Wondfo, Roche Diagnostics, ACON Biotech, InBios International, Bio-Rad Laboratories, DiaSorin Group, Siemens Healthineers, Thermo Fisher Scientific, Reszon Diagnostics International.
Segment by Type: NS1 Antigen Detection | IgM Antibody Detection | IgG Antibody Detection | Others
Segment by Application: Healthcare Industry | Public Health Sector | Others
Exclusive Industry Insights
Gross profit margin stratification: As a typical POCT IVD product, dengue rapid tests exhibit a stratified margin structure:
OEM/white-label supply (35–50% margin): Price-sensitive, large-volume bidding.
Own-brand + registration + distribution (50–65% margin): Brand premium and channel value.
Hospital terminal + government/international procurement (65–80% margin): Highest margins through brand and technical endorsement.
Technical bottleneck – NS1 sensitivity across serotypes: Dengue has four distinct serotypes (DENV-1 to DENV-4). Many rapid tests show 85–90% sensitivity for DENV-2 but only 65–75% for DENV-1 or DENV-3. High-quality NS1 tests (Abbott, SD Biosensor) use multiple monoclonal antibodies targeting conserved epitopes, achieving >92% sensitivity across all serotypes but at 2–3x higher cost.
Recent 6-month data (Oct 2025 – Mar 2026):
NS1 antigen detection fastest-growing (CAGR 8.2%), preferred for early diagnosis (days 1–5 of symptoms).
Combination tests (NS1 + IgM/IgG) now 45% of market, up from 28% in 2023.
Average price declined from US$ 4.50 to US$ 3.80 per test due to Chinese supplier competition.
User case – National dengue control program (Brazil, 5,000 health posts): Deploying NS1 rapid tests for suspected cases reduced average time-to-diagnosis from 3 days (lab confirmation) to 30 minutes. Early case detection improved patient outcomes (reduced progression to severe dengue by 28%). Program cost: US$ 12M annually; estimated hospitalization savings: US$ 28M.
Industry drivers: Climate change expanding mosquito vector range; healthcare systems shifting from confirmatory to screening diagnosis; international organization procurement (PAHO, WHO, UNICEF) for outbreak response; multi-pathogen testing (dengue + Zika + chikungunya) gaining traction.
Regional snapshot: Asia-Pacific leads with 52% revenue share (endemic: India, Thailand, Philippines, Indonesia). Latin America (Brazil, Mexico, Colombia) holds 28%. Africa fastest-growing (CAGR 8.5%) with expanding surveillance programs.
Conclusion
The dengue rapid test market grows steadily, driven by disease expansion, primary healthcare POCT adoption, and public health investment. Success depends on improving NS1 sensitivity across all serotypes, reducing raw material costs, and securing international procurement contracts. The projected US$ 952 million market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ